Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KF-0210 in Advanced Solid Tumors
NCT04713891Phase 1Completed
- Sponsor
- Keythera Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KF-0210 in solid tumor (advanced stage), colorectal cancer (CRC), lung cancer and 3 more (7 cohorts), sponsored by Keythera Pharmaceuticals. Primary endpoints: Adverse Events up to 1 year, Dose Limiting Toxicity and 5 more. Started Mar 2021; status: completed.
02
Drugs
KF-0210
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)lung cancerEsophageal Squamous Cell Carcinoma (ESCC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT04713891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04713891.